Investigating a new generation of ribozymes in order to target HCV.
For a long time nucleic acid-based approaches directed towards controlling the propagation of Hepatitis C Virus (HCV) have been considered to possess high potential. Towards this end, ribozymes (i.e. RNA enzymes) that specifically recognize and subsequently catalyze the cleavage of their RNA substrate present an attractive molecular tool. Here, the unique properties of a new generation of ribozymes are taken advantage of in order to develop an efficient and durable ribozyme-based technology with which to target HCV (+) RNA strands. These ribozymes resulted from the coupling of a specific on/off adaptor (SOFA) to the ribozyme domain derived from the Hepatitis Delta Virus (HDV). The former switches cleavage activity "on" solely in the presence of the desired RNA substrate, while the latter was the first catalytic RNA reported to function naturally in human cells, specifically in hepatocytes. In order to maximize the chances for success, a step-by-step approach was used for both the design and the selection of the ribozymes. This approach included the use of both bioinformatics and biochemical methods for the identification of the sites possessing the greatest potential for targeting, and the subsequent in vitro testing of the cleavage activities of the corresponding SOFA-HDV ribozymes. These efforts led to a significant improvement in the ribozymes' designs. The ability of the resulting SOFA-HDV ribozymes to inhibit HCV replication was further examined using a luciferase-based replicon. Although some of the ribozymes exhibited high levels of cleavage activity in vitro, none appears to be a potential long term inhibitor in cellulo. Analysis of recent discoveries in the cellular biology of HCV might explain this failure, as well as provide some ideas on the potential limits of using nucleic acid-based drugs to control the propagation of HCV. Finally, the above conclusions received support from experiments performed using a collection of SOFA-HDV ribozymes directed against HCV (-) strands.
Lévesque
Michel V
MV
Département de Biochimie, Faculté de Médecine et des Sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Lévesque
Dominique
D
Brière
Francis P
FP
Perreault
Jean-Pierre
JP
D000998:Antiviral Agents / Q000494:pharmacology*; D020134:Catalytic Domain; D019295:Computational Biology / Q000379:methods; D016679:Genome, Viral; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000635:transmission / Q000821:virology; D016086:Lentivirus / Q000235:genetics; D008957:Models, Genetic; D012313:RNA / Q000378:metabolism; D034622:RNA Interference; D016337:RNA, Catalytic / Q000737:chemistry* / Q000235:genetics; D012367:RNA, Viral / Q000235:genetics; D016914:Ribonuclease H / Q000378:metabolism; D014158:Transcription, Genetic
D000998:Antiviral Agents; D016337:RNA, Catalytic; D012367:RNA, Viral; D012313:RNA; D016914:Ribonuclease H